Screening for adrenal-endocrine hypertension: Overview of accuracy and cost-effectiveness

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 279-294

  Schwartz, Gary L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adrenal; Diagnostic accuracy; Screening; Secondary hypertension

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; FUROSEMIDE; METADRENALIN;

ADRENAL ENDOCRINE HYPERTENSION; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIURESIS; ENDOCRINE SYSTEM; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GOLD STANDARD; HEALTH CARE COST; HEALTH ECONOMICS; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; LIMIT OF DETECTION; NEGATIVE FEEDBACK; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; POSITIVE FEEDBACK; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESOURCE MANAGEMENT; REVIEW; RISK ASSESSMENT; SALT LOADING; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STEROID EXCRETION; TREATMENT DURATION;

ADRENAL GLAND DISEASES; ADRENAL GLAND NEOPLASMS; ADULT; CHILD; COST-BENEFIT ANALYSIS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MASS SCREENING; PHEOCHROMOCYTOMA; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 79955741300     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.02.001     Document Type: Review

References (46)

1. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
2. Kannel W.B. Blood pressure as a cardiovascular risk factor. JAMA 1996, 275:1571-1576.
3. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 2002, 33:862-875.
4. Tozawa M., Iseki K., Iseki C., et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003, 41:1341-1345.
5. Birns J., Kalra L. Cognitive function and hypertension. J Hum Hypertens 2009, 23:86-96.
6. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
7. Law M.R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. 10.1136/bmj.b1665.
8. Sinclair A.M., Isles C.G., Brown I., et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987, 147:1289-1293.
9. Rossi G.P., Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
10. Mandelblatt J.S., Fryback D.G., Weinstein M.C., et al. Assessing the effectiveness of health interventions for cost-effectiveness analysis. J Gen Intern Med 1997, 12:551-558.
11. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996, 276:1253-1258. for the Panel on Cost-Effectiveness in Health and Medicine.
12. Fletcher R.H., Fletcher S.W., Wagner E.H. Diagnosis. Clinical epidemiology, the essentials 1988, 42-75. Williams & Wilkins, Baltimore (MD). 2nd edition. N. Collins, C. Eckhart, G.N. Chalew (Eds.).
13. Holaj R., Zelinka T., Wichterle D., et al. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007, 25:1451-1457.
14. Diez J. Effects of aldosterone on the heart: beyond systemic hemodynamics?. Hypertension 2008, 52:462-464.
15. Reincke M., Rump L.C., Quinkler M., et al. Risk factors associated with low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009, 94:869-875.
16. Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
17. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
18. Kaplan N.M. Is there an unrecognized epidemic of primary aldosteronism? (Con). Hypertension 2007, 50:454-458.
19. Schwartz G.L., Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005, 51(2):386-394.
20. Mosso L., Carvajal C., Gonzalez A., et al. Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
21. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
22. Gallay B.J., Ahmad S., Xu L., et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
23. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
24. Strauch Z.T., Hampf M., Bernhardt R., et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the central Europe region. J Hum Hypertens 2003, 17:349-352.
25. Kaplan N.M. Primary aldosteronism. Clinical hypertension 2002, 459. Lippincott Williams & Wilkins, Baltimore (MD). 8th edition. N.M. Kaplan (Ed.).
26. Sawka A.M., Young W.F., Thompson G.B., et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258-261.
27. Montori V.M., Young W.F. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocinol Metab Clin North Am 2002, 31:619-632.
28. Tanabe A., Natruse M., Takagi G., et al. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003, 88:2489-2494.
29. Gordon R.D. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004, 22:251-255.
30. Schwartz G.L., Chapman A.B., Boerwinkle E., et al. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002, 48(11):1919-1923.
31. Montori V.M., Schwartz G.L., Chapman A.B., et al. Validity of the aldosterone-renin ratio to screen for primary aldosteronism. Mayo Clin Proc 2001, 76:877-882.
32. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007, 66:607-618.
33. Fogarty J., Engel C., Russo J., et al. Hypertension and pheochromocytoma testing: the association with anxiety orders. Arch Fam Med 1994, 3:55.
34. Sawka A.M., Gafni A., Thabane L., et al. The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 2004, 89:2859-2866.
35. Pacak K., Linehan W.M., Eisenhofer G., et al. NIH Conference. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001, 134:315-332.
36. Eisenhofer G., Kopin I.J., Goldstein D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004, 56:331-349.
37. Lenders J.W., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma. Which test is best?. JAMA 2002, 287:1427-1434.
38. Hickman P.E., Leong M., Chang J., et al. Plasma free metanephrines are superior to urine and plasma catecholamine metabolites for the investigation of pheochromocytoma. Pathology 2009, 41(2):173-177.
39. Pacak K., Eisenhofer G., Ahlman H., et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 2007, 3(2):92-102.
40. Peaston R.T., Graham K.S., Chambers E., et al. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta 2010, 411:546-552.
41. Eisenhofer G., Huysmans F., Pacak K., et al. Plasma metanephrines in renal failure. Kidney Int 2005, 67:668-677.
42. Perry C.G., Sawka A.M., Singh R., et al. The diagnostic accuracy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 2007, 66:703-708.
43. Grouzmann E., Drouard-Troalen L., Baudin E., et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol 2010, 162:951-960.
44. Eisenhofer G., Goldstein D.S., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true-from false-positive test results. J Clin Endocrinol Metab 2003, 88:2656-2666.
45. de Jong W.H., Eisenhofer G., Post W.J., et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009, 94:2841-2849.
46. Algeciras-Schimnich A., Preissner C.M., Young W.F., et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008, 93:91-95.